In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization